5997-01-3

Usage

General Description

2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(4-nitrophenyl)pyrrolidine-1-carboxamide is a complex chemical compound with a pyrrolidine-1-carboxamide backbone and additional functional groups including a 1,2,4-oxadiazol-5-yl ring and a 4-methylphenyl substituent. It also contains a 4-nitrophenyl group. 2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(4-nitrophenyl)pyrrolidine-1-carboxamide is likely to have significant interactions and effects due to its structural complexity and the presence of these various functional groups. It may hold potential for use in pharmaceutical research and development as a drug candidate, as the combination of these structural features could potentially impart specific biological activity and therapeutic properties. Further study and analysis of 2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-N-(4-nitrophenyl)pyrrolidine-1-carboxamide are warranted to fully understand its potential applications and effects.

InChI:InChI=1/C20H19N5O4/c1-13-4-6-14(7-5-13)18-22-19(29-23-18)17-3-2-12-24(17)20(26)21-15-8-10-16(11-9-15)25(27)28/h4-11,17H,2-3,12H2,1H3,(H,21,26)

Upstream product

• 26541-51-5 N-nitroso thiomorpholine 

Downstream Products

• 31898-55-2 [2-(5-nitro-thiophen-2-yl)-thiazol-4-ylmethylene]-thiomorpholin-4-yl-amine 
• 54738-42-0 {4-[2-(5-nitro-1-vinyl-1H-imidazol-2-yl)-vinyl]-benzylidene}-thiomorpholin-4-yl-amine 
• 75161-22-7 N-Cyclohexylidenamino-thiomorpholin 
• 75161-26-1 N-(p-Nitrobenzyliden)-amino-thiomorpholin 
• 75161-24-9 N-Benzylidenamino-thiomorpholin 
• 75161-25-0 N-(p-Aminobenzyliden)-amino-thiomorpholin 

Relevant academic research and scientific papers

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents

A series of linezolid analogues containing a hydrazone moiety were designed, synthesized and evaluated for their antibacterial activity. Most compounds exhibited more potent antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens as compared with linezolid and radezolid. Compounds 9a, 9c, 9f, 9g, 10m and 10t were more potent against tested clinical isolates of MRSA, MSSA, VRE and LREF as compared to linezolid. Compound 9a exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metabolism in human liver microsome. The most promising compound 9a showed remarkable antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.0675 mg/mL, respectively, which was 15- to 30-fold more potent than linezolid.

NEW DRUGS WITH ANTICHOLESTATIC ACTIVITY

New compounds belonging to the structural formula (I) are described. formula (I) in which R1, R2, A, Y and X are specified in the description, useful in the treatment of cholestasis and substantially devoid of antibacterial activity. The synthesis process of said compounds, the pharmaceutical compositions containing them and their use in therapy are also described.

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

ALPHA-MERCAPTOMETHYL-BENZENE PROPANAMIDES, PHARMACEUTICAL COMPOSITIONS AND USE

Novel α-mercaptomethyl-benzene propanamides of the formula STR1 wherein R 1 is selected from the group consisting of hydrogen and STR2 R 1 ' is selected from the group consisting of alkyl of 1 to 5 carbon atoms and aryl optionally substituted with at least one member of the group consisting of--OH,--NO 2, halogen and alkyl and alkoxy of 1 to 5 carbon atoms, X and X' are individually selected from the group consisting of hydrogen, alkyl and alkoxy of 1 to 5 carbon atoms,--OH, halogen and--CF 3, R 2 is selected from the group consisting of pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrahydrothiazinyl and hexahydroazepinyl, all optionally substituted with at least one member of the group consisting of alkyl and alkoxy of 1 to 5 carbon atoms,--OH,--NO. sub.2,--CF 3, halogen and acyl of an organic carboxylic acid of 1 to 7 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic activity, antidepression and anxiolytic properties.

On the Reactivity of Thiomorpholine and Alkyl Substituted Thiomorpholines 4. (On the Joint Action of Elementary Sulfur and Gaseous Ammonia on Ketones, 94.)

Thiomorpholine as well as alkyl substituted thiomorpholines and their S-dioxides, respectively, are transformed into the corresponding N-Aminothiomorpholines by nitrosation (1-5) followed by the reduction with zinc in acetic acid/acetic acid anhydride und